1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin, 2012, 62(6): 394-399.
|
3. |
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版). 中华外科杂志, 2022, 60(4): 273-309.
|
4. |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 中国实用外科杂志, 2020, 40(2): 121-138.
|
5. |
Yang C, Wu X, Liu J, et al. Nomogram based on platelet-albumin-bilirubin for predicting tumor recurrence after surgery in alpha-fetoprotein-negative hepatocellular carcinoma patients. J Hepatocell Carcinoma, 2023, 10: 43-55.
|
6. |
Oikonomou T, Goulis L, Doumtsis P, et al. ALBI and PALBI grades are associated with the outcome of patients with stable decompensated cirrhosis. Ann Hepatol, 2019, 18(1): 126-136.
|
7. |
Calderaro J, Petitprez F, Becht E, et al. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J Hepatol, 2019, 70(1): 58-65.
|
8. |
Minici R, Siciliano MA, Ammendola M, et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations (TACE) of the liver: The unexplored corner linking tumor microenvironment, biomarkers and interventional radiology. Cancers (Basel), 2022, 15(1): 257. doi: 10.3390/cancers15010257.
|
9. |
Kabir T, Ye M, Mohd Noor NA, et al. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes after curative resection for hepatocellular carcinoma. Int J Hepatol, 2019, 2019: 4239463. doi: 10.1155/2019/4239463.
|
10. |
Xiong S, Dong L, Cheng L. Neutrophils in cancer carcinogenesis and metastasis. J Hematol Oncol, 2021, 14(1): 173. doi: 10.1186/s13045-021-01187-y.
|
11. |
Lee W, Ko SY, Mohamed MS, et al. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med, 2019, 216(1): 176-194.
|
12. |
Nicolini D, Agostini A, Montalti R, et al. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol, 2017, 23(20): 3690-3701.
|
13. |
Wang C, Wang M, Zhang X, et al. The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Transl Med, 2020, 8(8): 541. doi: 10.21037/atm.2020.02.113.
|
14. |
Wang J, Chen Z, Wang L, et al. A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection. Sci Rep, 2022, 12(1): 8670. doi: 10.1038/s41598-022-12518-5.
|
15. |
Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer, 2017, 111: 176-181.
|
16. |
Li DY, Hao XY, Ma TM, et al. The prognostic value of platelet-to-lymphocyte ratio in urological cancers: a meta-analysis. Scientific Reports, 2017, 7: 15387. doi: 10.1038/s41598-017-15673-2.
|
17. |
Zhang M, Huang XZ, Song YX, et al. High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: a meta-analysis. Biomed Res Int, 2017, 2017: 9503025. doi: 10.1155/2017/9503025.
|
18. |
Lai Q, Melandro F, Larghi Laureiro Z, et al. Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: a systematic review and meta-analysis. World J Gastroenterol, 2018, 24(15): 1658-1665.
|
19. |
Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ, 2019, 7: e7132. doi: 10.7717/peerj.7132.
|
20. |
Silva JPM, Coelho FF, Cassenote AJF, et al. Preoperative inflammatory markers as prognostic predictors after hepatocellular carcinoma resection: data from a western referral center. BMC Surg, 2022, 22(1): 329. doi: 10.1186/s12893-022-01779-6.
|
21. |
Hofbauer SL, Stangl KI, de Martino M, et al. Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma. Br J Cancer, 2014, 111: 1526-1531.
|
22. |
Takemura K, Fukushima H, Ito M, et al. Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma. Urol Oncol, 2019, 37: 108-115.
|
23. |
Yang F, Zhang S, Yang H, et al. Prognostic significance of gamma-glutamyltransferase in patients with resectable esophageal squamous cell carcinoma. Dis Esophagus, 2015, 28: 496-504.
|
24. |
Sun L, Gu M, Cai J, et al. Combining γ-GT, PIVKA-Ⅱ and AFP to predict long-term prognosis in patients with hepatocellular carcinoma after hepatectomy. Clin Exp Pharmacol Physiol, 2023, 50(4): 287-297.
|
25. |
Faber W, Sharafi S, Stockmann M, et al. Long-term results of liver resection for hepatocellular carcinoma in noncirrhotic liver. Surgery, 2013, 153(4): 510-517.
|
26. |
国家科技部传染病防治重大专项课题《病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究》专家组. 肝细胞癌肝切除术后复发预防和治疗中国专家共识(2020版). 中国实用外科杂志, 2021, 41(1): 20-30.
|
27. |
陈姚, 陈义发, 刀辰冉, 等. 肝细胞癌根治性切除术后复发患者不同局部治疗方法疗效比较. 中华肝脏外科手术学电子杂志, 2018, 7(4): 305-310.
|
28. |
Komorowski AL, Hsu CC, Julka KD, et al. AFP role in predicting recurrence of hepatocellular carcinoma after living donor liver transplantation in HCV patients. Neoplasma, 2018, 65(3): 455-460.
|
29. |
Magro B, Pinelli D, De Giorgio M, et al. Pre-transplant alpha-fetoprotein >25.5 and its dynamic on waitlist are predictors of HCC recurrence after liver transplantation for patients meeting Milan criteria. Cancers (Basel), 2021, 13(23): 5976. doi: 10.3390/cancers13235976.
|
30. |
Lei Z, Li J, Wu D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria. JAMA Surg, 2016, 151(4): 356-363.
|
31. |
Xing H, Zhang WG, Cescon M, et al. Defining and predicting early recurrence after liver resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford), 2020, 22(5): 677-689.
|
32. |
Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol, 2018, 69(6): 1284-1293.
|